Filtered By:
Condition: Heart Failure
Drug: Beta-Blockers

This page shows you your search results in order of date.

Order by Relevance | Date

Total 190 results found since Jan 2013.

Differential Cardiovascular Outcomes of Each Antihypertensive Drug Class in Patients With Hypertension and Breast Cancer Undergoing Doxorubicin-Containing Chemotherapy
CONCLUSION: RAS inhibitors are preferred for the treating hypertension and improving CV outcomes in patients with hypertension and breast cancer undergoing DOX-containing chemotherapy, particularly in patients with comorbid diabetes. However, CCBs are equivalent to RAS inhibitors and are more favorable than BBs and TDs in terms of improving CV outcomes.PMID:37704380 | DOI:10.4048/jbc.2023.26.e34
Source: Journal of Breast Cancer - September 13, 2023 Category: Cancer & Oncology Authors: Hui-Jeong Hwang Sang-Ah Han Source Type: research

Blocking interleukin-6 Trans-Signaling in AF: Promises and Challenges
Atrial fibrillation (AF) stands as the most prevalent cardiovascular disease, posing significant risks of stroke, heart failure, and other complications that contribute to morbidity and mortality. While traditionally research on AF has primarily focused on electrophysiological components like ionic currents and the Ca2+ handling system, treatment strategies have mainly revolved around the rate-limiting beta-blockers and Ca2+ channel blockers, or rhythm-control methods such as cardioversion, antiarrhythmics, and catheter ablation.
Source: Heart Rhythm - September 9, 2023 Category: Cardiology Authors: Enrique Martinez, Na Li Source Type: research

Impact of age on characteristics, performance measures and outcomes of inpatients for heart failure in Beijing, China
ConclusionsHF patients aged ≥75 years had distinct clinical profiles, received worse in-hospital therapies and experienced higher in-hospital and 1 year mortality.
Source: ESC Heart Failure - August 2, 2023 Category: Cardiology Authors: Cong Yuan, Liu He, Xin Du, Chao Jiang, Shi ‐Jun Xia, Xin Zhao, Song‐Nan Li, Cai‐Hua Sang, De‐Yong Long, Jian‐Zeng Dong, Chang‐Sheng Ma Tags: Original Article Source Type: research

First-line diuretics versus other classes of antihypertensive drugs for hypertension
CONCLUSIONS: When used as first-line agents for the treatment of hypertension, thiazides and thiazide-like drugs likely do not change total mortality and likely decrease some morbidity outcomes such as cardiovascular events and withdrawals due to adverse effects, when compared to beta-blockers, calcium channel blockers, ACE inhibitors, and alpha-blockers.PMID:37439548 | DOI:10.1002/14651858.CD008161.pub3
Source: Cochrane Database of Systematic Reviews - July 13, 2023 Category: General Medicine Authors: Marcia Reinhart Lorri Puil Douglas M Salzwedel James M Wright Source Type: research

Clinical Efficacy and Safety of Early Intravenous Administration of Beta-Blockers in Patients Suffering from Acute ST-Segment Elevation Myocardial Infarction Without Heart Failure Undergoing Primary Percutaneous Coronary Intervention: A Study-Level Meta-Analysis of Randomized Clinical Trials
ConclusionIntravenous beta-blockers improved the MSI, decreased the risk of VT/VF in the first 24 h, and were associated with increased LVEF at 1 week and 6 months following PCI. In particular, intravenous beta-blockers started before PCI is beneficial for patients with LAD lesions.
Source: Cardiovascular Drugs and Therapy - April 1, 2023 Category: Cardiology Source Type: research

Atrial fibrillation, cancer and anticancer drugs
Arch Cardiovasc Dis. 2023 Mar 11:S1875-2136(23)00058-X. doi: 10.1016/j.acvd.2023.02.005. Online ahead of print.ABSTRACTActive cancer is associated with an increased risk of atrial fibrillation (AF), which varies depending on the pre-existing substrate (particularly in older patients), the cancer type and stage, and the anticancer therapeutics being taken. To date, studies have not been able to identify the individual contribution of each factor. During anticancer drug therapy, AF may occur with a frequency of ≈ 15-20% according to several factors, including the patient's baseline cardiovascular toxicity risk and the AF-d...
Source: Cancer Control - March 31, 2023 Category: Cancer & Oncology Authors: Jonaz Font Paul Milliez Alexandre-Boudjema Ouazar Frederikus A Klok Joachim Alexandre Source Type: research

Development and validation of dynamic models to predict postdischarge mortality risk in patients with acute myocardial infarction: results from China Acute Myocardial Infarction Registry
Conclusions We established dynamic risk prediction models incorporating adverse event and medications. The nomograms may be useful instruments to help prospective risk assessment and management of AMI. Trial registration number NCT01874691.
Source: BMJ Open - March 29, 2023 Category: General Medicine Authors: Lv, J., Wang, C., Gao, X., Yang, J., Zhang, X., Ye, Y., Dong, Q., Fu, R., Sun, H., Yan, X., Zhao, Y., Wang, Y., Xu, H., Yang, Y., on behalf of the China Acute Myocardial Infarction Registry study group Tags: Open access, Cardiovascular medicine Source Type: research